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Intensive care unit (VSKI) study group & the Korean study group on respiratory failure (KOSREF)Abstract
Background: The role of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) as a prognostic factor in patients
admitted to the intensive care unit (ICU) is not yet fully established. We aimed to determine whether NT-pro-BNP is
predictive of ICU mortality in a multicenter cohort of critically ill patients.
Methods: A total of 1440 patients admitted to 22 ICUs (medical, 14; surgical, six; multidisciplinary, two) in 15 tertiary or
university-affiliated hospitals between July 2010 and January 2011 were assessed. Patient data, including NT-pro-BNP levels
and Simplified Acute Physiology Score (SAPS) 3 scores, were recorded prospectively in a web-based database.
Results: The median age was 64 years (range, 53–73 years), and 906 (62.9%) patients were male. The median NT-pro-BNP
level was 341 pg/mL (104–1,637 pg/mL), and the median SAPS 3 score was 57 (range, 47–69). The ICU mortality
rate was 18.9%, and hospital mortality was 24.5%. Hospital survivors showed significantly lower NT-pro-BNP values
than nonsurvivors (245 pg/mL [range, 82–1,053 pg/mL] vs. 875 pg/mL [241–5,000 pg/mL], respectively; p < 0.001). In
prediction of hospital mortality, the area under the curve (AUC) for NT-pro-BNP was 0.67 (95% confidence interval [CI],
0.64–0.70) and SAPS 3 score was 0.83 (95% CI, 0.81–0.85). AUC increment by adding NT-pro-BNP is minimal and likely
no different to SAPS 3 alone.
Conclusions: The NT-pro-BNP level was more elevated in nonsurvivors in a multicenter cohort of critically ill patients.
However, there was little additional prognostic power when adding NT-pro-BNP to SAPS 3 score.
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B-type natriuretic peptide (BNP) is released from cardiac
ventricles in response to increased wall tension [1]. Meas-
urement of BNP is useful in establishing the diagnosis of
heart failure [2]. N-terminal pro-B-type natriuretic peptide
(NT-pro-BNP), a precursor of BNP, provides prognostic in-
formation superior to that obtained from BNP in patients
with myocardial infarction [3]. NT-pro-BNP has been* Correspondence: cmcksc@catholic.ac.kr
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reproduction in any medium, provided the orshown to be a good prognostic marker in patients with car-
diac disease [4].
NT-pro-BNP levels are elevated not only in patients
with cardiac disease but also in critically ill patients.
Okkonen et al. [5] showed that the NT-pro-BNP level
on patient admission is commonly elevated in patients
with acute respiratory failure. Wang et al. [6] reported
that elevated NT-pro-BNP levels may prove to be a
powerful predictor of mortality in septic patients. NT-
pro-BNP level may be a prognostic marker in critically
ill patients [7-10]. However, few large-scale multicenter
studies have assessed NT-pro-BNP as a prognostic factor.
Also, little is known regarding the correlation between NT-
pro-BNP and clinical parameters in critically ill patients.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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is elevated. Thus, by using a large cohort we aimed to as-
sess the prognostic value of NT-pro-BNP level in patients
admitted to the intensive care unit (ICU) and analyzed the
relationship between the level of NT-pro-BNP and clinical
parameters.
Methods
We used data from the “Validation of simplified acute
physiology score 3 in Korean ICUs” (VSKI) study cohort.
VSKI was a prospective multicenter cohort study that
aimed to validate the simplified acute physiology score
(SAPS) 3 in Korean ICU patients that was performed by
the Korean Study group on Respiratory Failure (KOSREF)
between July 1st, 2010 and January 31st, 2011. VSKI in-
cluded 22 ICUs (medical, 14; surgical, six; multidisciplinary,
two) in 15 tertiary or university-affiliated hospitals. The
study was approved by the institutional review board of the
Seoul St. Mary’s Hospital, Samsung Medical Center, Sever-
ance Hospital, Keimyung University Dongsan Hospital, Aju
University Hospital, Konkuk University Chungju Hospital,
Korea University Ansan Hospital, Armed Forces Capital
Hospital, Chung-Ang University Hospital, Gangneung
Asan Hospital, Hallym University Sacred Heart Hospital,
Gyeongsang National University Hospital, Ewha Womans
University Hospital, Bundang CHA Hospital and Asan
Medical Center. The requirement for informed consent
was waived because of the observational nature of
the study.
Patients
All patients admitted to the 22 ICUs during the study
period were eligible for the present study. Patients whose
NT-pro-BNP levels were measured on ICU admission
were included in the study. We excluded patients who
were younger than 17 years. Patients who were trans-
ferred from other participating ICUs were also excluded.A total of 4,617 patients were enrolled in 
VSKI study.
1440 patients were included in this study.
NT-pro-BNP levels were measured upon 
ICU admission in 1,643 patients.
Figure 1 Enrolled patients.For patients with two or more admissions to the ICU
during the same hospital stay, only the data from the first
admission were used. Patients whose ICU or hospital mor-
tality was uncertain were excluded in the analysis.Data collection
Patient data were recorded prospectively in a web-based
database. We obtained data on demographic characteris-
tics (age, gender, body weight, and height), underlying dis-
ease, SAPS 3, sequential organ failure assessment (SOFA)
score, severe sepsis, or septic shock on ICU admission,
acute lung injury (ALI) or acute respiratory distress syn-
drome (ARDS) on ICU admission, admission category
(medical or surgical), admission diagnosis, organ support
(mechanical ventilation, renal replacement therapy, and
use of vasopressors), length of ICU stay and hospital stay,
and mortality on ICU and hospital discharge. The medical
history of each patient was reviewed thoroughly, and the
initial vital signs on ICU admission were recorded. Labora-
tory data, including complete blood cell count, chemistry,
and arterial blood gas analysis were collected within 24 h
of ICU admission. Illness severity was assessed using the
SAPS 3 score. Blood NT-pro-BNP level was determined
together with all SAPS 3 variables.Data analysis
We compared the level of NT-pro-BNP on admission in
patients with hospital survivors and nonsurvivors. Then, we
compared the mortality rate according to the quintile of
NT-pro-BNP. We also compared the level of NT-pro-BNP
according to the reason of ICU admission and analyzed
correlation between NT-pro-BNP and clinical parameters.
We calculated prognostic power of NT-pro-BNP to predict
mortality and compared with that of SAPS 3 score. Finally,
we analyzed if there was additive benefit when combining
NT-pro-BNP with SAPS 3 score.ICU mortality data were not 
available in 82 patients.
Hospital mortality data were not 
available in 121 patients.
Table 1 Baseline characteristics of patients (n = 1440)
Characteristics Median (IQR) or No. (%)










Status at ICU admission
Severe sepsis or septic shock 309 (21.5)
ALI or ARDS 123 (8.5)
Admission category
Medical 835 (58.0)
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Because most of the data were not normally distributed, all
results are presented as medians and interquartile ranges
(IQRs), or as numbers (percentages) of patients. Differences
between groups were assessed using chi-squared test or
Fisher’s exact test for categorical variables, as appropriate.
For continuous variables, differences between two groups
were assessed by the Mann–Whitney U-test and differences
among four groups were assessed by the Kruskal–Wallis
test. Correlations between continuous variables were as-
sessed by Spearman’s test. Receiver operating characteristic
(ROC) curves were generated for NT-pro-BNP and SAPS
3. SAPS 3 and NT-pro-BNP were evaluated for their associ-
ation with hospital survival by logistic regression analysis.
NT-pro-BNP was transformed into a natural log (ln) scale
because of the wide range of levels. All tests were two sided,
and P values less than 0.05 were considered to indi-
cate statistical significance. All statistical analyses were
performed using PASW Statistics, version 17 (SPSS,
Chicago, IL, USA).Surgical 605 (42.0)
Reason for ICU admission
Basic & observational** 583 (40.5)
Cardiovascular 264 (18.3)
Digestive 62 (4.3)




NT-pro-BNP (pg/mL) 341 (104–1,637)
SAPS 3 score 57 (47–69)
SOFA score 7 (3–11)
ICU day 7 (4–16)
ICU mortality 272 (18.9)
Hospital day 18 (10–35)
Hospital mortality 353 (24.5)
**Basic and observational intensive care were defined as management of a
patient in the ICU for surveillance, simple weaning from a ventilator after
surgery, routine post-surgery care, or needing complex nursing care or
monitoring of drug intoxication without organ dysfunction.
IQR = interquartile range; IHD = ischemic heart disease; CHF = congestive heart
failure; DM = diabetes mellitus; CRF = chronic renal failure; ICU = intensive care
unit; ALI = acute lung injury; ARDS = acute respiratory distress syndrome; SAPS
3 = Simplified Acute Physiology Score (SAPS) 3.Results
NT-pro-BNP levels in 1,643 patients were measured upon
ICU admission. Among them, ICU mortality data were
available for 1,561 patients, and hospital mortality data were
available in 1440 patients. Thus, 1440 patients were in-
cluded in the study (Figure 1). The median age was 64 years
(range, 53–73 years), and 906 (62.9%) were male. On ICU
admission, 309 (21.5%) patients had severe sepsis or septic
shock, and 123 (8.5%) were ALI or ARDS. The median
NT-pro-BNP was 341 pg/mL (range, 104–1,637 pg/mL),
and the median SAPS 3 score was 57 (range, 47–69). The
ICU mortality rate was 18.9%, and the hospital mortality
rate was 24.5%. The baseline characteristics of the patients
are shown in Table 1.
ICU survivors had significantly lower NT-pro-BNP values
than ICU nonsurvivors (268 pg/mL [range, 80–1,140 pg/
mL] vs. 1,021 pg/mL [range, 232–6,256 pg/mL], respect-
ively; p < 0.001). Likewise, hospital survivors were charac-
terized by significantly lower NT-pro-BNP values than
hospital nonsurvivors (245 pg/mL [range, 82–1,053 pg/mL]
vs. 875 pg/mL [range, 241–5,000 pg/mL], respectively;
p < 0.001). Figure 2 shows box and whisker plots for
hospital survival.
The NT-pro-BNP level was significantly different
according to the reason for ICU admission (p < 0.001;
Figure 3). The level of NT-pro-BNP was highest in pa-
tients whose reason for ICU admission was a renal compli-
cation (7,946 pg/mL [range, 890–24,118 pg/mL]), followed
by a cardiovascular complication (1,154 pg/mL [range,
190–5,217 pg/mL]). The level of NT-pro-BNP was signifi-
cantly different according to underlying disease or clinical
situation (Table 2). Significant correlations between NT-pro-BNP level and many clinical parameters were found
(Table 3).
ROC curve analysis was used to identify the NT-pro-
BNP level and SAPS 3 score on admission that best pre-
dicted hospital mortality. An NT-pro-BNP concentration
of 514.8 pg/mL had a sensitivity of 62% and specificity
of 66% for predicting hospital mortality. Positive predictive
value was 0.37 and negative predictive value was 0.84. The
area under the ROC curve was 0.67 (95% confidence
Figure 2 Box and whisker plots for hospital survival. The NT-pro-BNP level was significantly higher in nonsurvivors than survivors.
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sensitivity of 81% and specificity of 70% for predicting
hospital mortality. The area under the ROC curve was
0.83 (95% CI, 0.81–0.85). AUC increment by adding NT-
pro-BNP is minimal and likely no different to SAPS 3
alone (Table 4, Figure 4).Figure 3 Box and whisker plots for the reason for ICU admission. NT-Almost all clinical characteristics differed significantly
according to NT-pro-BNP level (Table 5). The percentage
of ischemic heart disease, congestive heart failure, and
chronic renal failure were increased according to NT-pro-
BNP level quartile. Among the reasons for ICU admission,
the rates of cardiovascular and renal complications werepro-BNP levels varied according to the reason for ICU admission.
Table 2 Level of NT-pro-BNP (pg/mL) according to the
underlying disease or clinical situation
Variables No. (%) Median (IQR) p-value
Female 534 (37.1%) 420 (137–1,780) 0.008
Male 906 (62.9%) 292 (84–1,520)
Cirrhosis (−) 1,283 (89.1%) 385 (109–1,808) <0.001
Cirrhosis (+) 157 (10.9%) 187 (83–526)
Hypertension (−) 896 (62.2%) 276 (86–1,208) <0.001
Hypertension (+) 544 (37.8%) 456 (125–2,384)
IHD (−) 1,280 (88.9%) 296 (93–1,309) <0.001
IHD (+) 160 (11.1%) 967 (251–4,894)
CHF (−) 1,332 (92.5%) 299 (93–1,382) <0.001
CHF (+) 108 (7.5%) 1,226 (413–8,346)
DM (−) 1,077 (74.8%) 284 (94–1,223) <0.001
DM (+) 363 (25.2%) 611 (129–3,373)
CRF (−) 1,296 (90.0%) 276 (91–1,127) <0.001
CRF (+) 144 (10.0%) 2,799 (773–16,768)
Cancer (−) 896 (62.2%) 390 (101–2,214) 0.027
Cancer (+) 544 (37.8%) 285 (108–1,024)
Severe sepsis or
septic shock (−)
1,131 (78.5%) 269 (85–1,112) <0.001
Severe sepsis or
septic shock (+)
309 (21.5%) 890 (206–7,946)
ALI or ARDS (−) 1,317 (91.5%) 309 (100–1,389) <0.001
ALI or ARDS (+) 123 (8.5%) 827 (191–3,504)
Elective surgery 502 (34.9%) 195 (78–492) <0.001
Emergency surgery 103 (7.2%) 233 (97–981)
Surgery (−) 835 (58.0%) 604 (148–3,170)
MV (−) 770 (53.5%) 264 (83–1,064) <0.001
MV (+) 670 (46.5%) 456 (129–2,542)
Vasoactive drug (−) 904 (62.8%) 237 (79–828) <0.001
Vasoactive drug (+) 536 (37.2%) 721 (178–3,720)
RRT (−) 1,268 (88.1%) 278 (93 – 1,164) <0.001
RRT (+) 172 (11.9%) 2,377 (413–18,751)
IQR = interquartile range; IHD = ischemic heart disease; CHF = congestive heart
failure; DM = diabetes mellitus; CRF = chronic renal failure; ALI = acute lung
injury; ARDS = acute respiratory distress syndrome; MV =mechanical
ventilation; RRT = renal replacement therapy.
Table 3 Correlations between NT-pro-BNP and clinical
parameters
Clinical parameters Correlation coefficient (p) p-value
Age 0.19 <0.001
Lowest MAP −0.22 <0.001
Highest HR 0.25 <0.001
Highest BT 0.13 <0.001
Lowest platelet −0.11 <0.001
Highest total bilirubin −0.07 0.006
Highest BUN 0.40 <0.001
Highest Cr 0.33 <0.001
Lowest Na −0.12 <0.001
Highest K 0.14 <0.001
Lowest pH −0.09 0.001
Lowest HCO3
− −0.17 <0.001
Lowest PaO2 −0.25 <0.001
Highest PaCO2 −0.06 0.029
Highest GCS −0.10 <0.001
Lowest PF ratio −0.26 <0.001
Input 0.07 0.013
Urine output −0.11 <0.001
MAP =mean arterial pressure, HR = heart rate, BT = body temperature, BUN =
blood urea nitrogen, Cr = creatinine, Na = sodium, K = potassium, GCS =
Glasgow Coma Scale, PF ratio = PaO2/FIO2 ratio.
Table 4 The area under the ROC curve in prediction of
hospital mortality
AUC 95% CI p-value
NT-pro-BNP 0.671 0.639-0.704 <0.001
SAPS3 0.828 0.805-0.852 <0.001
SAPS3 + lnNT-pro-BNP (continuous variable) 0.831 0.808-0.855 <0.001
SAPS3 + lnNT-pro-BNP (categorical variable) 0.835 0.812-0.858 <0.001
ROC = Receiver operating characteristic; AUC = area under the curve; CI =
confidence interval; SAPS 3 = Simplified Acute Physiology Score (SAPS) 3.
Natural-log-transformed (ln) NT-pro-BNP was used as the continuous variable
or divided by the quartile and used as the categorical variable.
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SAPS 3 score, SOFA score, ICU day, and ICU mortality
also increased according to NT-pro-BNP level quartile.
Hospital mortality also differed significantly according to
NT-pro-BNP level (11.4% in the first quartile, 18.3% in the
second quartile, 29.7% in the third quartile, and 38.6% in
the fourth quartile; p < 0.001; Figure 5).
Logistic regression was performed to determine whether
the NT-pro-BNP level has additional power to predict
hospital mortality in combination with the SAPS 3 score.
The odds ratio of the SAPS 3 score alone was 1.10. Whencombined with NT-pro-BNP, the odds ratio of the SAPS 3
score was 1.09 (Tables 6 and 7). There was little change in
the odds ratio and 95% CI of SAPS 3 when combined with
NT-pro-BNP.
Discussion
In the present study, we showed that the serum level of
NT-pro-BNP on admission has weak prognostic power
and little additive prognostic power when combined with
SAPS 3 score. Although previous studies [7-10] have shown
that the NT-pro-BNP level can be a prognostic factor in
critically ill patients, the present study represents the largest
scale study.
In the present study, the serum NT-pro-BNP level on
admission was significantly higher in ICU nonsurvivors
Figure 4 Receiver operating characteristic (ROC) curve analysis for hospital mortality. The area under the ROC curve was 0.67 for the
NT-pro-BNP level and 0.83 for the SAPS 3 score. Combine of NT-pro-BNP level and SAPS 3 score resulted in little additional power.
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increased with increasing levels of NT-pro-BNP. Our
findings are compatible with previous reports. All four
studies [7-10] consistently showed similar results.
Compared with previous studies, the prognostic power
of NT-pro-BNP was similar or somewhat weaker. Almog
et al. [7] showed that the area under the ROC curve of
NT-pro-BNP levels for prediction of mortality was 0.75
(95% CI, 0.62–0.88). Meyer et al. [8] showed that the
area under the ROC curve was 0.70 (95% CI, 0.64–0.77).
In the present study, the area under the ROC curve was
0.67 (95% CI, 0.64–0.70). The reason for the lower prog-
nostic power in the present study is unknown. To ad-
dress this issue, additional validation of the prognostic
power of NT-pro-BNP is needed. One possible explan-
ation is that the population enrolled in the two previous
studies may have been biased. Thus, the prognostic power
of NT-pro-BNP might be overestimated. In the study by
Almog and colleagues [7], the number of patients analyzed
was only 78, and all were admitted to the medical ICU in
a single center. In the study by Meyer and colleagues [8],
289 patients in only a single center were evaluated. Al-
though Meyer et al. [8] included the entire spectrum of
medical patients with a critical illness, many had cardiac
disease because the ICU in that study was in the Depart-
ment of Cardiology. In those patients, the NT-pro-BNP
level was more likely to have prognostic power. Compared
with the previous two studies, a much larger number of
number of patients were enrolled in the present study(n = 1440), and they were admitted not only to the medical
ICU but also to the surgical ICU at multiple centers. Sin-
gle measurement of the NT-pro-BNP level on admission
can be an attractive prognostic factor if it is sufficiently
powerful because other scoring systems, such as the SAPS
3, are somewhat complex and time consuming. Unfortu-
nately, our data suggest that the NT-pro-BNP level alone
is not a powerful prognostic factor in patients admitted to
the ICU.
Along with its weak power for prediction of mortality,
our data suggest that the NT-pro-BNP level plays little
adjunct role when combined with SAPS 3 score. This re-
sult is not compatible with previous reports. Meyer et al.
[8] showed that the SAPS 2 score and the NT-pro-BNP
level were independently associated with hospital sur-
vival in a logistic regression model. Kotanidou et al. [9]
reported that the Acute Physiology and Chronic Health
Evaluation (APACHE) II score and NT-pro-BNP level
were independent predictors of mortality in multiple lo-
gistic regression analysis. The reason for the NT-pro-BNP
level having little adjunct role in this study when com-
bined with SAPS 3 is unknown. One possible explanation
is that, in the present study, the NT-pro-BNP level was
well correlated with many clinical parameters that are
components of SAPS 3. Thus, prognosis may be already
predicted enough by only SAPS 3 score.
In the present study, when combined with the SAPS
3 score, the AUC was increased little. As shown in
Tables 3, many clinical parameters and characteristics
Table 5 Comparison of clinical characteristics according to the quartile of NT-pro-BNP level
NT-pro-BNP (pg/mL) < 104 104–341 341–1,637 > 1,637 p-value
Number of patients 360 360 360 360
Age, years 59 (49–69) 63 (52–72) 67 (55–76) 68 (56–75) < 0.001
Male 250 (69.4) 223 (61.9) 213 (59.2) 220 (61.1) 0.024
Comorbidities
Cirrhosis 47 (13.1) 62 (17.2) 29 (8.1) 19 (5.3) < 0.001
Hypertension 118 (32.8) 120 (33.3) 142 (39.4) 164 (45.6) 0.001
IHD 18 (5.0) 29 (8.1) 49 (13.6) 64 (17.8) < 0.001
CHF 5 (1.4) 18 (5.0) 37 (10.3) 48 (13.3) < 0.001
DM 75 (20.8) 71 (19.7) 94 (26.1) 123 (34.2) < 0.001
CRF 8 (2.2) 16 (4.4) 35 (9.7) 85 (23.6) < 0.001
Cancer 130 (36.1) 164 (45.6) 144 (40.0) 106 (29.4) < 0.001
Status at ICU admission
Severe sepsis or septic shock 42 (11.7) 64 (17.8) 75 (20.8) 128 (35.6) < 0.001
ALI or ARDS 18 (5.0) 27 (7.5) 28 (7.8) 50 (13.9) < 0.001
Admission category
Medical 171 (47.5) 159 (44.2) 212 (58.9) 293 (81.4) < 0.001
Surgical 189 (52.5) 201 (55.8) 148 (41.1) 67 (18.6) < 0.001
Reason for ICU admission
Basic & observational** 166 (46.1) 174 (48.3) 156 (43.3) 87 (24.2) < 0.001
Cardiovascular 40 (11.1) 47 (13.1) 58 (16.1) 119 (33.1) < 0.001
Digestive 22 (6.1) 14 (3.9) 15 (4.2) 11 (3.1) 0.236
Hepatic failure 29 (8.1) 39 (10.8) 14 (3.9) 4 (1.1) < 0.001
Neurologic 10 (2.8) 5 (1.4) 9 (2.5) 11 (3.1) 0.519
Renal 1 (0.3) 2 (0.6) 3 (0.8) 15 (4.2) < 0.001
Respiratory 61 (19.6) 66 (18.3) 90 (25.0) 93 (25.8) 0.004
SAPS 3 score 50 (39–61) 55 (47–65) 58 (49–68) 68 (57–78) < 0.001
SOFA score 5 (2–9) 6 (3–10) 6 (3–11) 10 (6–13) < 0.001
ICU day 5 (3–12) 6 (4–16) 7 (4–17) 9 (4–20) < 0.001
ICU mortality 28 (7.8) 55 (15.3) 76 (21.1) 113 (31.4) < 0.001
Hospital day 16 (9–31) 17 (11–35) 17 (11–37) 19 (10–38) 0.106
Hospital mortality 41 (11.4) 66 (18.3) 107 (29.7) 139 (38.6) < 0.001
**Basic and observational intensive care was defined as the patient being in the ICU for surveillance, simple weaning from a ventilator after surgery, routine post-
surgery care, or needing complex nursing care or monitoring drug intoxication without organ dysfunction.
IHD = ischemic heart disease; CHF = congestive heart failure; CPF = chronic pulmonary disease; DM = diabetes mellitus; CRF = chronic renal failure; ICU = intensive
care unit; ALI = acute lung injury; ARDS = acute respiratory distress syndrome.
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BNP level. Thus, when analyzed using the combin-
ation of the SAPS 3 and NT-pro-BNP level, the power
of NT-pro-BNP was offset. For example, renal compli-
cation is the reason whose level of NT-pro-BNP is
highest among the reason of ICU admission (Figure 3).
This suggests that the prognostic power of NT-pro-
BNP is due partly to the poor prognosis of renal fail-
ure patients. However, blood urea nitrogen, creatinine,
pH, HCO3
−, and urine output are components of the
SAPS 3 score. The NT-pro-BNP level was also well
correlated with these parameters, which are importantprognostic factors in patients with renal failure. The
poor prognosis of renal failure is already sufficiently
predicted by the SAPS3 score. Thus, NT-pro-BNP had
only a limited effect upon combination with the SAPS
3 score.
Conversely to usual biomarkers, severity score have
been proven to be poorly calibrated to predict individual
mortality. This may be because of differences in the pa-
tient case-mix or changing medical practice over time
[11]. For example, SAPS 3 score showed mixed result in
the external validation studies [12-17]. In this study, this

























Figure 5 Hospital mortality according to NT-pro-BNP level.
Mortality increased with the quartile of the NT-pro-BNP level.
Table 7 Logistic regression for prediction of hospital
mortality (SAPS 3 + NT-pro-BNP)
Odds ratio 95% CI p-value
SAPS 3 score 1.09 1.08-1.11 < 0.001
lnNT-pro-BNP 1.13 1.05-1.21 0.001
Goodness of fit (Hosmer–Lemeshow) chi-squared p-value = 0.146. Natural-log-
transformed (ln) NT-pro-BNP was used as the continuous variable.
CI = confidence interval; SAPS 3 = Simplified Acute Physiology Score (SAPS) 3.
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the ROC curve was only 0.83. For NT-pro-BNP, there
has been also variability for the power to predict mortal-
ity in previous studies. Thus, further validation study for
NT-pro-BNP is mandatory.
The limitation of this study is potential selection bias. In
this study, there were no definite criteria for the measure-
ment of NT-pro-BNP. Basically, this study was multicenter
observational study. Thus, in some centers, NT-pro-BNP
was measured routinely for all patients, while in other cen-
ters, NT-pro-BNP was measured by clinician’s preference.
Thus, selection bias for enrollment of patients may exist.
However, the level of NT-pro-BNP was variable, which
suggests that patients who were unlikely to have cardiac
disease were also enrolled. Baseline characteristics also
showed that the percentage of ischemic heart disease or
heart failure was not high (11.1 and 7.5%, respectively),
which supports selection bias for patients with cardiac
disease was unlikely to occur.
The present study is valuable in that it was of a multi-
center, prospective design. In the present study, multiple
ICU settings (medical or surgical or multidisciplinary) in
multiple centers were analyzed. Thus, the enrolled popu-
lation may be representative of real-world ICU patients.
To be a good prognostic marker, NT-pro-BNP should be
validated in a large-scale multicenter study. Our results
provide valuable information regarding the limited role
of NT-pro-BNP in general ICU patients. Further investi-
gation of the role of NT-pro-BNP in critically ill patients
with various clinical characteristics is needed.Table 6 Logistic regression for prediction of hospital
mortality (SAPS 3 alone)
Odds ratio 95% CI p-value
SAPS 3 score 1.10 1.08-1.10 < 0.001
Goodness of fit (Hosmer–Lemeshow) chi-squared p-value = 0.119. CI = confidence
interval; SAPS 3 = Simplified Acute Physiology Score (SAPS) 3.Conclusions
In conclusion, the NT-pro-BNP level was more elevated
in nonsurvivors in a multicenter cohort of critically ill
patients. However, there was little additional prognostic
power when adding NT-pro-BNP to SAPS 3 score. Fur-
ther investigation of NT-pro-BNP as a prognostic factor
in patients admitted to the ICU is needed.
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